Ⅰ期恶性卵巢生殖细胞肿瘤中分期手术与辅助化疗的作用:MITO-9研究
MITO-9研究纳入144例Ⅰ期恶性卵巢生殖细胞肿瘤患者,分析辅助化疗与手术分期的作用。结果显示不完全手术分期与复发相关(P<0.05;OR 2.37),卵黄囊成分是生存预测因素(P<0.05),监测组与标准治疗组5年OS分别为94.1%与93.8%。
要点
- 不完全腹膜手术分期与复发相关(P<0.05;OR 2.37)。
- 监测组与标准治疗组5年OS分别为94.1%与93.8%。
- 卵黄囊组织学是生存预测因素(P<0.05)。
核心结论
- 本研究显示监测似乎不影响生存,化疗应保留用于复发且可获高治愈率。
- 不完全腹膜手术分期与复发相关,卵黄囊组织学使预后更差。
研究设计与样本
- 研究收集MITO中心144例Ⅰ期恶性卵巢生殖细胞肿瘤患者的数据并进行分析。
主要发现
- 55例(38.2%)为无性细胞瘤,49例(34%)为未成熟畸胎瘤,26例(18.1%)为卵黄囊瘤,14例(9.7%)为混合性肿瘤。
- 73例(50.7%)接受手术加化疗,71例(49.3%)仅接受手术。
- 44例患者未接受化疗,即使按推荐方案本应接受化疗。
- 94例(65.3%)接受腹膜手术分期,23例(15.9%)出现复发。
- Cox回归分析中不完全手术分期与复发相关(P<0.05;OR 2.37)。
关键数值与推荐
- 除ⅠA期无性细胞瘤和ⅠA期1级未成熟畸胎瘤仅推荐监测外,手术继以铂类化疗是恶性卵巢生殖细胞肿瘤的标准治疗。
临床怎么用
- 作者认为监测似乎不影响生存,化疗应保留用于复发且可获高治愈率。
- 作者指出不完全腹膜手术分期与复发相关,卵黄囊组织学使预后更差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgery followed by platinum-based chemotherapy is the standard of care for MOGCTs, except for stage IA dysgerminoma and stage IA grade 1 immature teratoma where surveillance only is recommended. The role of adjuvant chemotherapy and surgical staging is debated. PATIENTS AND METHODS: Data from 144 patients with stage I MOGTs were collected among MITO centers (Multicenter Italian Trials in Ovarian Cancer) and analyzed. RESULTS: Fifty-five (38.2%) patients were affected by dysgerminomas, 49 (34%) by immature teratomas, 26 (18.1%) by yolk sac tumors and 14 (9.7%) by mixed tumors. Seventy-three (50.7%) patients receive surgery plus chemotherapy, while 71 (49.3%) patients underwent surgery alone. The latter group included 32 dysgerminomas (14 IA-13 Ix, 3 IB, and 2 IC), 34 immature teratomas (20 1A-13 IA grade 1, 6 Ix, 1 IB, and 7 IC), 4 mixed tumors and 1 yolk sac tumor. Forty-four patients did not received chemotherapy, even if it would have been indicated by recommended approach. 94 (65.3%) patients received peritoneal surgical staging. Twenty-three (15.9%) developed a recurrence. Incomplete surgical staging was associated with recurrence (P < 0.05; OR 2.37) at Cox regression analysis. Seven patients died. Four patients were affected by yolk sac tumors, two by mixed tumors and one by immature teratoma. Five patients died for disease, one for acute leukemia and one for suicide. Prognostic parameter analyses showed that yolk sac component is a predictor for survival (P < 0.05). Five-years OS rates were 96.8% and 88.7% in the surgically staged and the incomplete staged group, respectively, while 93.8% and 94.1% in the standard treatment and in the surveillance group, respectively. CONCLUSIONS: This study shows that surveillance seems not to affect survival; chemotherapy should be reserved for relapse resulting in high cure rate. Incomplete peritoneal surgical staging is associated with recurrence. Yolk sac histology worsens the prognosis.
引用
- Mangili G, Sigismondi C, Lorusso D, et al. The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study. Ann Oncol. 2017. PMID: 27803008. doi:10.1093/annonc/mdw563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。